JMP Securities Maintains Market Outperform on Inhibrx, Lowers Price Target to $35
JMP Securities analyst Benjamin Chaiken maintains Inhibrx (NASDAQ:INBX) with a Market Outperform and lowers the price target from $40 to $35.
Credit Suisse Reiterates Outperform on Inhibrx, Maintains $46 Price Target
Credit Suisse analyst Judah Frommer reiterates Inhibrx (NASDAQ:INBX) with a Outperform and maintains $46 price target.
NorthStar Medical Radioisotopes And Inhibrx Enter Collaboration Agreement For Development And Production Of Radiopharmaceutical Candidates
BELOIT, Wis. and SAN DIEGO, Jan. 4, 2023 /PRNewswire/ -- NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for
Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday
Gainers
Satixfy Communications Ltd. (NYSE: SATX) jumped 96.4% to settle at $51.70 on Thursday.
Inhibrx Announces Updated Efficacy And Safety Data From The Expansion Cohorts In The Phase 1 Trial Of INBRX-109 For The Treatment Of Chondrosarcoma
Inhibrx, Inc. (NASDAQ:INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced updated efficacy and safety data from the ongoing
Evercore ISI Group Maintains Outperform on Inhibrx, Raises Price Target to $60
Evercore ISI Group analyst Gavin Clark-Gartner maintains Inhibrx (NASDAQ:INBX) with a Outperform and raises the price target from $54 to $60.
S&P 500 Rises 100 Points; Nasdaq Up 3%
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite climbing more than 300 points on Tuesday.
Nasdaq Surges 250 Points; Crude Oil Rises Sharply
U.S. stocks traded higher midway through trading, with the Nasdaq Composite climbing more than 250 points on Tuesday.
US Stocks Open Higher As Dow Jumps 550 Points
U.S. stocks traded higher this morning, with the Dow Jones climbing more than 550 points on Tuesday.
Inhibrx’s Experimental Drug For Inherited Disease Capable For Accelerated FDA Approval, Shares Surge
Based on discussions with the FDA, Inhibrx Inc (NASDAQ:INBX) has the potential to pursue accelerated approval for INBRX-101 for emphysema due to…